Skip to main content

Table 1 Incidence of clinical and severe malaria in the control group of the Phase III trial

From: Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study

 

Low (PP ≤ 5 %)

Moderate (PP 5–40 %)

High (PP > 40 %)

Overall

Sites

Kilifi (Kenya), Korogwe (Tanzania), Manhiça (Mozambique)

Bagamoyo (Tanzania), Lambarene (Gabon), Agogo (Ghana), Kintampo (Ghana), Lilongwe (Malawi)

Siaya (Kenya), Kombewa (Kenya), Nanoro (Burkina Faso)

 

Control group incidence (95 % CI) of clinical malaria per child per year in each 6–month follow-up period for infants receiving the first vaccine dose at age 6–12 weeks

 0–6 months

na

0.74 (0.65–0.83)

2.82 (2.62–3.03)

1.20 (1.13–1.28)

 6–12 months

0.13 (0.088–0.185)

0.96 (0.87–1.06)

3.69 (3.46–3.93)

1.54 (1.46–1.62)

 12–18 months

0.20 (0.14–0.27)

0.91 (0.82–1.01)

3.35 (3.13–3.59)

1.50 (1.42–1.59)

Control group incidence (95 % CI) of clinical malaria per child per year in each 6–month follow-up period for children receiving the first vaccine dose at age 5–17 months

 0–6 months

0.058 (0.030–0.101)

1.10 (1.00–1.19)

3.32 (3.12–3.53)

1.56 (1.48–1.64)

 6–12 months

0.13 (0.09–0.19)

1.49 (1.39–1.60)

4.59 (4.35–4.83)

2.11 (2.02–2.20)

 12–18 months

na

1.14 (1.04–1.24)

3.46 (3.25–3.67)

1.67 (1.59–1.75)

Incidence of severe malaria per 1000 children (95 % CI) per year across the whole follow-up period

 Infants receiving the first vaccine dose at age 6–12 weeks

2.51 (0.06–14.10)

27.2 (17.0–41.1)

56.3 (41.7–74.5)

39.0 (27.7–38.4)

Children receiving the first vaccine dose at age 5–17 months

4.62 (0.95–13.5)

39.0 (29.8–50.2)

61.2 (47.1–78.2)

39.3 (32.7–46.7)

  1. Clinical malaria defined as illness accompanied by a temperature of at least 37.5 °C or reported fever in the last 24 h and asexual P. falciparum parasites in the blood at a density of >0 parasites/mm3
  2. Severe malaria defined as P. falciparum parasites in the blood at a density of >5000 parasites/mm3
  3. na not available, PP parasite prevalence